Genetic variations can influence the onset of Alzheimer’s disease by up to a decade in individuals with a predisposition linked to the APP gene, according to a study published in the journal Alzheimer’s & Dementia.
Researchers led by the Institut de Recerca Sant Pau (IR Sant Pau) in Barcelona analyzed clinical and genetic data from 1,057 participants to determine why symptoms emerge at different ages.
The cohort included 957 people with Down syndrome and 100 individuals with a specific duplication of the APP gene on chromosome 21, which causes a rare form of early-onset hereditary Alzheimer’s, EFE Salud reported. While this gene duplication is known to drive the production of amyloid-beta peptides—a hallmark of the disease—the timing of initial symptoms typically ranges between 40 and 65 years old.
The study assessed the effect of the APOE gene and 77 other genetic variants to calculate an accumulated risk index. Results indicated that the APOE ε2 allele is associated with a later onset, while the APOE ε4 variant and a higher burden of risk variants are linked to earlier symptom manifestation.

“We knew that having an extra copy of the APP gene is directly related to the development of Alzheimer’s disease, but we did not fully understand why some people present the first symptoms much earlier than others,” said Danna Perlaza, a researcher at IR Sant Pau, as noted by CatalunyaPress, according to Diario en Positivo.
| Patient Group | Median Age (High Risk) | Median Age (Low Risk) | Difference |
|---|---|---|---|
| APP Duplication | 49.4 years | 58.8 years | 9.4 years |
| Down Syndrome | 50.1 years | 60.1 years | 10.0 years |
The researchers identified that these variations particularly affect biological pathways related to amyloid metabolism and angiogenesis, the process of forming new blood vessels, according to IM Médico. These findings may help refine the selection of participants for future preventive clinical trials.
“This helps us to better understand the complexity of Alzheimer’s and to identify factors that could be useful to anticipate its onset,” explained Olivia Belbin, head of the Molecular Neurodegeneration group at IR Sant Pau.
Researchers emphasized that identifying these modifiers is essential for intervention, as the disease can develop in the brain for years before clinical signs appear, according to Servimedia. Understanding how these genetic factors interact provides new potential strategies for delaying the disease, noted Oriol Dols-Icardo, a researcher in the Neurobiology of Dementias group.